BCL2 and acute myeloid leukemia: Venetoclax (VEN) is a potent inhibitor of anti-apoptotic B-cell leukemia/lymphoma-2 (BCL-2) which is overexpressed in leukemia stem cells [1,2] Clinical data have demonstrated that VEN-based combination chemotherapy with hypomethylating agents (HMAs) or low-dose cytarabine (LDAC) leads to more desirable outcomes than HMAs or LDAC alone in patients with acute myeloid leukemia (AML) [3,4,5,6].